更新于：2024-07-03

Cancer immunotherapies(Cell Genesys, Inc.)

更新于：2024-07-03

概要

研发状态

概要

基本信息

药物类型

治疗性疫苗

别名

GVAX Leukemia、GVAX Pancreas、GVAX Prostate

+ [5]

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [1]

在研适应症

急性髓性白血病胰腺癌

非在研适应症

非小细胞肺癌转移性胰腺腺癌胰腺继发性恶性肿瘤

原研机构

Cell Genesys, Inc.

在研机构

Aduro BioTech, Inc.

ANI Pharmaceuticals, Inc.

Dana-Farber Cancer Institute, Inc.

非在研机构

Cell Genesys, Inc.

Chinook Therapeutics, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

项与 Cancer immunotherapies(Cell Genesys, Inc.) 相关的临床试验

NCT02004262 / Completed临床2期

A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma

Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma

开始日期2014-02-05

申办/合作机构

Aduro BioTech, Inc.

[+1]

NCT01417000 / Completed临床2期

A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma

Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for metastatic pancreatic cancer.

开始日期2011-09-21

申办/合作机构

Aduro BioTech, Inc.

[+1]

NCT01088789 / Active, not recruiting临床2期IIT

A Safety and Feasibility Trial of Boost Vaccinations of a Lethally Irradiated, Allogeneic Pancreatic Tumor Cell Vaccine Transfected With the GM-CSF Gene

The purpose of this study is to evaluate the safety and feasibility of long term boost vaccination of a lethally irradiated, allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene alone or given in combination with either a single intravenous dose or daily metronomic oral doses of cyclophosphamide for the treatment of patients with surgically resected adenocarcinoma of the head, neck, tail or the uncinate process of the pancreas.

开始日期2010-04-20

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

100 项与 Cancer immunotherapies(Cell Genesys, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Cancer immunotherapies(Cell Genesys, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Cancer immunotherapies(Cell Genesys, Inc.) 相关的专利（医药）

登录后查看更多信息

项与 Cancer immunotherapies(Cell Genesys, Inc.) 相关的文献（医药）

2021-01-01·Central European journal of urology

Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology

Review

作者: Lasek, Witold ; Zapała, Łukasz

INTRODUCTION:

Therapeutic cancer vaccines have been recognized as a promising treatment option in clinical oncology for nearly three decades. However, despite many efforts, only one cancer vaccine - sipuleucel-T, activating the anti-PAP (prostatic acid phosphatase) immune response, has obtained Food and Drug Administration (FDA) approval.

MATERIAL AND METHODS:

This review describes the most advanced research on the use of therapeutic cancer vaccines in the treatment of prostate cancer.

RESULTS:

In addition to sipuleucel-T, which was approved in urologic oncology in 2010, four cancer vaccines were and have been tested in phase III clinical trials in patients with metastatic castration resistant prostate cancer (mCRPC): GVAX (prostate cancer variant) containing irradiated prostate cancer cell, PPV peptide vaccine, PCVAC/PCa dendritic cell-based vaccine and PROSTVAC anti PSA (prostate-specific antigen) vaccine. This review compares the most promising and best-studied cancer vaccines: sipuleucel-T and PROSTVAC. Currently, both vaccines have been tested in combination with other therapeutic approaches, including check point inhibitors.

CONCLUSIONS:

It seems possible that the efficacy of sipuleucel-T and PROSTVAC could be increased in combination therapy with other medications.

2020-05-01·Cancer immunology research1区 · 医学

Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer

1区 · 医学

Article

作者: Müller, Thomas ; Lemmens, Ed ; Nair, Nitya ; Jaffee, Elizabeth M. ; Brockstedt, Dirk G. ; Chang, Serena ; Whiting, Chan ; Chen, Shih-Yu ; Le, Dung T. ; Murphy, Aimee

Abstract:

The identification of biomarkers for patient stratification is fundamental to precision medicine efforts in oncology. Here, we identified two baseline, circulating immune cell subsets associated with overall survival in patients with metastatic pancreatic cancer who were enrolled in two phase II randomized studies of GVAX pancreas and CRS-207 immunotherapy. Single-cell mass cytometry was used to simultaneously measure 38 cell surface or intracellular markers in peripheral blood mononuclear cells obtained from a phase IIa patient subcohort (N = 38). CITRUS, an algorithm for identification of stratifying subpopulations in multidimensional cytometry datasets, was used to identify single-cell signatures associated with clinical outcome. Patients with a higher abundance of CD8+CD45RO−CCR7−CD57+ cells and a lower abundance of CD14+CD33+CD85j+ cells had improved overall survival [median overall survival, range (days) 271, 43–1,247] compared with patients with a lower abundance of CD8+CD45RO−CCR7−CD57+ cells and higher abundance of CD14+CD33+CD85j+ cells (77, 24–1,247 days; P = 0.0442). The results from this prospective–retrospective biomarker analysis were validated by flow cytometry in 200 patients with pancreatic cancer enrolled in a phase IIb study (P = 0.0047). The identified immune correlates provide potential prognostic or predictive signatures that could be employed for patient stratification.

2019-09-15·Clinical cancer research : an official journal of the American Association for Cancer Research1区 · 医学

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

1区 · 医学

Article

作者: Andrew H. Ko ; Elizabeth M. Jaffee ; Tony Reid ; Daniel A. Laheru ; Sandy Ferber ; Hedy Kindler ; Amanda Enstrom ; Nitya Nair ; Paul E. Oberstein ; Zev A. Wainberg ; Dung T. Le ; Todd Crocenzi ; Michael A Morse ; Aimee Murphy ; Vincent J Picozzi ; Noelle K. LoConte ; Herbert Zeh ; Erkut Borazanci ; Colin D. Weekes ; Dirk G Brockstedt ; Andrea Wang-Gillam ; Chan Whiting ; Benjamin Musher

Abstract:

Purpose::

Limited options exist for patients with advanced pancreatic cancer progressing after 1 or more lines of therapy. A phase II study in patients with previously treated metastatic pancreatic cancer showed that combining GVAX pancreas (granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells) with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes expressing mesothelin) resulted in median overall survival (OS) of 6.1 months, which compares favorably with historical OS achieved with chemotherapy. In the current study, we compared Cy/GVAX + CRS-207, CRS-207 alone, and standard chemotherapy in a three-arm, randomized, controlled phase IIb trial.

Patients and Methods::

Patients with previously treated metastatic pancreatic adenocarcinoma were randomized 1:1:1 to receive Cy/GVAX + CRS-207 (arm A), CRS-207 (arm B), or physician's choice of single-agent chemotherapy (arm C). The primary cohort included patients who had failed ≥2 prior lines of therapy, including gemcitabine. The primary objective compared OS between arms A and C in the primary cohort. The second-line cohort included patients who had received 1 prior line of therapy. Additional objectives included OS between all treatment arms, safety, and tumor responses.

Results::

The study did not meet its primary efficacy endpoint. At the final study analysis, median OS [95% confidence interval (CI)] in the primary cohort (N = 213) was 3.7 (2.9–5.3), 5.4 (4.2–6.4), and 4.6 (4.2–5.7) months in arms A, B, and C, respectively, showing no significant difference between arm A and arm C [P = not significant (NS), HR = 1.17; 95% CI, 0.84–1.64]. The most frequently reported adverse events in all treatment groups were chills, pyrexia, fatigue, and nausea. No treatment-related deaths occurred.

Conclusions::

The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy. (ClinicalTrials.gov ID: NCT02004262)See related commentary by Salas-Benito et al., p. 5435

项与 Cancer immunotherapies(Cell Genesys, Inc.) 相关的新闻（医药）

2023-02-17

·生物谷

《科学·转化医学》：让癌细胞“窝里斗”！哈佛团队将癌细胞改造成抗癌杀手，能诱导强力的抗肿瘤免疫

研究团队使用了人源GBM细胞系构建了hThTC1，并在人源化小鼠上测试了其治疗效果。结果显示，在切除原位肿瘤后，注射hThTC能够有效抑制复发肿瘤的生长并显著延长小鼠的生存期。这代表着活肿瘤细胞疫苗具疫苗，是免疫学赋予人类最强大的武器之一，拥有疫苗之后，许多传染病的流行得到有效控制，天花也已经绝迹。而现在，科学家们希望用这个武器来对付肿瘤。肿瘤在发生发展的过程中积累了多种突变，其中一些突变会引起蛋白质序列的变化，也就是所谓的肿瘤新抗原。免疫系统可以识别其中一些抗原，从而对肿瘤发动攻击，这使得学界萌生了使用肿瘤新抗原疫苗增强机体抗肿瘤免疫应答的想法。但是在既往的临床试验中，使用灭活肿瘤细胞进行免疫接种，并未给患者带来足够的临床获益[1-3]，因此还需进一步改良。近期，由哈佛医学院布莱根妇女医院干细胞和转化免疫治疗中心Khalid Shah领衔的研究团队在《科学·转化医学》上发表最新研究成果[4]：研究者在体外对肿瘤细胞进行改造，敲除IFN-β受体（IFNAR1），并使其过表达IFN-β和GM-CSF，再将经过改造的肿瘤细胞输回荷瘤小鼠体内，被改造后的肿瘤细胞能够抵达肿瘤病灶，并诱导强力的抗肿瘤免疫应答，显著延长了荷瘤小鼠的生存期。论文首页截图曾有研究将肿瘤细胞灭活后作为疫苗使用，但是灭活的肿瘤细胞失去归巢至体内病灶处的能力，并且也失去了表达蛋白质与递呈抗原给CD8+T细胞的能力，这意味着灭活肿瘤细胞疫苗难以在肿瘤病灶处激起足够强大的细胞免疫应答。因此，Khalid Shah研究团队决定开发一款基于活细胞的肿瘤细胞疫苗。研究者选用了恶性程度高的脑胶质母细胞瘤（GBM）作为测试模型，首先在体外对GBM细胞系CT2A进行改造，使其分泌能够改造肿瘤微环境的IFN-β和能够诱导DC细胞的GM-CSF，同时为了避免自我损伤，敲除了肿瘤细胞上的IFNAR1，被改造后的肿瘤细胞被称为ThTC。在体外共培养试验中，ThTC能直接杀伤未经改造的GBM细胞，说明ThTC可以凭借其分泌的IFN-β直接发挥抗肿瘤作用。 ThTC可以直接抑制肿瘤细胞的生长为了评估ThTC细胞能否在体内发挥抗肿瘤作用，研究团队构建了原位GBM小鼠模型，结果显示，接受ThTC免疫的小鼠，在接种WT GBM肿瘤细胞后，脑中没有形成可见的肿瘤，并且没有小鼠因为脑肿瘤死亡。这说明ThTC的直接抗肿瘤作用以及诱导抗肿瘤免疫作用最终完全消除了肿瘤。研究团队又给第一次荷瘤后幸存的小鼠对侧大脑再次接种肿瘤，观察小鼠是否具有免疫记忆，如能排除再次接种的肿瘤，则说明ThTC可以诱导免疫记忆。结果显示，接受ThTC治疗的小鼠完全消除了再次接种的肿瘤，而如果清除小鼠的CD4+T细胞，免疫记忆就无法形成，表明ThTC治疗可诱导对肿瘤的免疫记忆，且免疫记忆的形成依赖于CD4+T细胞。 ThTC治疗能完全清除肿瘤，并诱导T细胞免疫记忆接下来，研究团队为接种GBM的小鼠进行手术，切除瘤灶之后再给予小鼠ThTC治疗，从而在更贴近临床实际情况的状态下，评估ThTC治疗的价值。结果显示，接受ThTC治疗的小鼠复发率更低，生存期显著延长；对肿瘤浸润免疫细胞进行检测发现，接受ThTC治疗的小鼠肿瘤部位浸润的免疫细胞数量显著增加。转录组测序分析表明，接受ThTC治疗后，肿瘤中Ⅰ型干扰素通路、抗原递呈通路基因和免疫刺激性分子表达均明显上调。这些数据表明，ThTC治疗重塑了肿瘤免疫微环境，使其更偏向抗肿瘤免疫应答。 ThTC可降低肿瘤复发率并重塑肿瘤免疫微环境接下来研究团队测试了活肿瘤细胞疫苗在其他肿瘤中的效果，如针对肺癌的LLC-ThTC：结果显示，接种LLC-ThTC有效地抑制了肺癌进展，并显著延长了小鼠的生存期；在幸存小鼠的脑中再次接种肿瘤，模拟肺癌脑转移时，先前接受过LLC-ThTC免疫的小鼠能再次有效清除肿瘤。这表明，ThTC有望用于治疗多种肿瘤，并有效抑制肿瘤转移和复发。 LLC-ThTC不仅能够抑制原位肺癌生长，还能够帮助机体抵御脑转移瘤为了将上述小鼠中的发现转化到临床场景，研究团队使用了人源GBM细胞系构建了hThTC1，并在人源化小鼠上测试了其治疗效果。结果显示，在切除原位肿瘤后，注射hThTC能够有效抑制复发肿瘤的生长并显著延长小鼠的生存期。这代表着活肿瘤细胞疫苗具有临床转化潜力。在人源化小鼠模型中，ThTC展现了治疗潜力从作用机制来看，经过改造的活肿瘤细胞可以主动归巢至肿瘤病灶处，在肿瘤局部释放IFN-β直接杀死肿瘤细胞，并通过GM-CSF增加肿瘤浸润DC细胞的数量，被杀死的肿瘤细胞释放出肿瘤新生抗原，进而被DC细胞递呈给T细胞，进一步促进抗肿瘤免疫应答。总而言之，这项研究揭示了工程化改造肿瘤细胞作为肿瘤疫苗的潜力，尤其是ThTC这种活肿瘤细胞疫苗的转化应用前景值得期待。 ThTC的作用机制总结参考文献： 1.R. O. Dillman, A. N. Cornforth, G. I. Nistor, E. F. McClay, T. T. Amatruda, C. Depriest, Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. J. Immunother.Cancer 6, 19 (2018). 2. D. T T. Le, V . J. Picozzi, A. H. Ko，et.al Resultsfrom a phase IIb, randomized, multicenterstudy of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Clin. Cancer Res. 25, 5493–5502 (2019). 3. A. A. Wu, K. M. Bever, W. J. Ho, E. J. Fertig, et.al , A phase II study of allogeneic GM-CSFtransfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer. Clin. Cancer Res. 26, 5129–5139 (2020) 4. Chen KS, Reinshagen C, Van Schaik TA, et al. Bifunctional cancer cell-based vaccine concomitantly drives direct tumor killing and antitumor immunity. Sci Transl Med. 2023;15(677):eabo4778. doi:10.1126/scitranslmed.abo4778

疫苗免疫疗法临床研究

2022-05-23

·药明康德

助力乳腺癌和前列腺癌早期诊断，两款AI诊断软件获FDA批准

近日，RadNet宣布其两家子公司开发的两款AI诊断软件——DeepHealth Saige-DX乳腺X射线摄影（mammography）产品和Quantib前列腺2.0 MRI AI算法获美国FDA批准。 Saige-Dx是已获批的Saige-Q工作列表分类软件的升级版，是一种癌症检测工具，使放射科医生能够使用AI更有效地检测是否存在乳腺癌。DeepHealth强大的新AI技术可自动识别乳房X光照片中的可疑病变，并为每个可疑病变和整个病例分配可疑级别。它有助于及早发现和诊断乳腺癌。 Saige-Dx的获批是基于此前一项研究的数据，在该研究中18名放射科医生在使用Saige-Dx时取得更好的表现，体现在使用该软件时检测到的癌症百分比的增加和较低的假阳性率。“Saige-Dx建立在我们先进的深度学习算法之上。正如去年Nature Medicine的一篇文章中所述，我们高度准确的AI显示出比专业的乳腺成像放射科医生早一到两年发现癌症的能力。Saige-Dx的获批代表着在推进癌症护理方面又向前迈进了一步。使用我们的软件工具的医生给出了积极的反馈，该软件使他们在解释乳房X光检查图像时更加准确和高效，”DeepHealth首席执行官兼联合创始人Gregory Sorensen医学博士说。 Quantib Prostate是一种基于AI的软件解决方案，可推进MRI前列腺报告工作流程。该解决方案附带一套工具来提高报告质量和速度。Quantib Prostate的重大升级已获得FDA的510（K）认证。 RadNet总裁兼首席执行官Howard Berger博士说：“我们对两家子公司DeepHealth和Quantib的旗舰产品获批感到非常高兴。AI将对放射学和癌症产生变革性影响，我们致力于为患者和医疗保健提供者提供这些进步。在未来几十年，我们相信这些AI工具将在癌症的早期发现和诊断中发挥重要作用，从而提高生存率和改善治疗效果。” 参考资料： 1. RadNet Artificial Intelligence Subsidiaries, DeepHealth and Quantib, Obtain FDA Clearance for Mammography and Prostate AI Tools，Retrieved May 16, 2022, from https://www.globenewswire.com/news-release/2022/05/16/2443575/10985/en/RadNet-Artificial-Intelligence-Subsidiaries-DeepHealth-and-Quantib-Obtain-FDA-Clearance-for-Mammography-and-Prostate-AI-Tools.html 内容来源于网络，如有侵权，请联系删除，谢谢

诊断试剂放射疗法

2015-02-26

·BioSpace

Aduro Biotech Collaborates With Leaders In Cancer Research On Investigator-Sponsored Phase 2 Trial Combining Aduro’s Innovative Immunotherapies With Anti-PD-1 Technology To Treat Patients With Advanced Pancreatic Cancer

- Combination Immunotherapeutic Regimen Designed to Enhance Cancer Fighting Competency of Immune Cells - BERKELEY, Calif.--(BUSINESS WIRE)--Aduro Biotech, Inc. today announced the initiation of an investigator-sponsored Phase 2 clinical trial of the company’s immuno-oncology product candidates GVAX Pancreas and CRS-207 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab), a monoclonal antibody against programmed death-1 receptor (PD-1). The first patient has been enrolled in the trial that will be conducted at up to five U.S. clinical trial sites. “For some time, we have recognized and embraced the power of combination strategies for immuno-oncology and this trial will evaluate expanding our lead combination to include Opdivo, the first-in-class anti-PD-1” GVAX Pancreas and CRS-207 are designed to stimulate an immune response against a tumor, and nivolumab is designed to remove an immuno-suppressive mechanism that cancer cells have developed against the immune system. Aduro believes the combination of CRS-207 and GVAX Pancreas with nivolumab may improve clinical outcomes because of their complementary mechanisms of action. The randomized, controlled STELLAR trial (Safety and Therapeutic Efficacy of Live-attenuated Listeria/GVAX with Anti-PD1 Regimen) will enroll approximately 88 adults with metastatic pancreatic cancer who have had one prior chemotherapy regimen for metastatic disease. The trial will include two arms: Arm A with CRS-207/GVAX Pancreas vaccine and nivolumab and Arm B with CRS-207/GVAX Pancreas vaccine. The primary objective of this study is to compare the overall survival (OS) of patients in Arm A and Arm B. Secondary endpoints include evaluation of clinical and immune response and safety. For more information, please visit ClinicalTrials.gov (Identifier: NCT02243371). The trial is supported by Stand up to Cancer (SU2C)-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research; Pancreatic Cancer Action Network – AACR Research Acceleration Network Grant, supported by Fredman Family Foundation; and Bristol-Myers Squibb. SU2C is a program of the Entertainment Industry Foundation. “For some time, we have recognized and embraced the power of combination strategies for immuno-oncology and this trial will evaluate expanding our lead combination to include Opdivo, the first-in-class anti-PD-1,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “While we continue our efforts to evaluate GVAX Pancreas and CRS-207 in our Phase 2b ECLIPSE trial as an effective treatment for pancreatic cancer, we look forward to generating data in yet another combination for potential future applications of our technologies.” “The Pancreatic Cancer Action Network is thrilled to have provided initial funding that has been leveraged for this important program,” said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. “In an effort to double pancreatic cancer survival by 2020, we are investing in projects that have the potential to improve the treatment landscape of pancreatic cancer and ultimately increase survival.” “Stand Up To Cancer is excited not only that this immunotherapy clinical trial has begun patient enrollment, one of the 120 clinical trials we have launched or completed,” stated SU2C President and CEO Sung Poblete, R.N, Ph.D., “but that it involves collaboration by two distinct biotechnology firms to study the combination of two proprietary immunotherapies. Stand Up To Cancer is proud to have facilitated this level of multi-institutional and corporate collaboration, which is at the core of SU2C’s research model and its mission to benefit cancer patients faster.” Last year, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Aduro’s pancreatic cancer combination treatment consisting of CRS-207 and GVAX Pancreas. According to the FDA, a Breakthrough Therapy designation is for a drug candidate that treats a serious or life-threatening condition and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint over available therapies. Separately, Aduro is currently conducting a 240 patient Phase 2b clinical trial (ECLIPSE; identifier NCT02004262) in metastatic pancreatic cancer patients who have received at least one line of therapy. The randomized, controlled 3-arm trial will involve approximately 20 clinical trial sites in the United States and Canada and will evaluate the safety, immune response and efficacy of the combination immunotherapy of GVAX Pancreas in combination with CRS-207 compared to chemotherapy or to CRS-207 as a monotherapy. The primary endpoint of the trial is overall survival. About CRS-207 CRS-207 is one of a family of product candidates based on Aduro’s live-attenuated, double-deleted (LADD) Listeria monocytogenes immuno-oncology platform that are designed to induce potent innate and adaptive immune responses. CRS-207 has been engineered to express the tumor-associated antigen mesothelin, which is over-expressed in many cancers including mesothelioma and pancreatic, non-small cell lung, ovarian and gastric cancers. About GVAX Pancreas GVAX Pancreas is one of a family of GVAX vaccines derived from human cancer cell lines that are genetically modified to express granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune system-stimulating cytokine. GVAX Pancreas is derived from human pancreatic cancer cell lines and is designed to activate specific T cell immunity to pancreatic cancer antigens, including mesothelin. About the Stand Up To Cancer Initiative Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress. About the Pancreatic Cancer Action Network The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase survival for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double Pancreatic Cancer Survival by 2020. Together, we can Wage Hope in the fight against pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics and better treatments and increase chances of survival. For more information, go to . About Aduro Aduro Biotech, Inc. is a private, clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. Aduro’s lead platform is based on proprietary strains of live-attenuated, double-deleted (LADD) Listeria monocytogenes that induce a potent innate immune response and have been engineered to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. Aduro has received Breakthrough Therapy designation from the FDA for its lead LADD regimen, CRS-207 in combination with GVAX Pancreas in pancreatic cancer. The company is evaluating the proprietary immuno-oncology combination in the ongoing Phase 2b ECLIPSE clinical trial and has additional ongoing clinical trials with its LADD platform in mesothelioma and glioblastoma. The company is also developing clinical candidates using synthetic small molecule immune modulators that are designed to activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit . Contacts Aduro Biotech, Inc.Sylvia Wheeler, 510-809-9264SVP, Corporate AffairsorMedia Contact:Angela Bitting, 925-202-6211a.bitting@comcast.net Help employers find you! Check out all the jobs and post your resume.

疫苗合作抗体突破性疗法First in Class

100 项与 Cancer immunotherapies(Cell Genesys, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	临床2期	加拿大	Chinook Therapeutics, Inc.	2013-12-17
转移性胰腺腺癌	临床2期	美国	Aduro BioTech, Inc.	2011-09-21
胰腺继发性恶性肿瘤	临床2期	美国	Aduro BioTech, Inc.	2011-09-21
急性髓性白血病	临床2期	美国	Dana-Farber Cancer Institute, Inc.	2010-03-03
非小细胞肺癌	临床2期	-	Cell Genesys, Inc.	2003-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2020	N/A	转移性肾细胞癌	58	Immunotherapies (IO)	夢簾壓願廠遞構鏇淵膚(廠鹹築膚鹹遞襯獵鑰壓) = 衊製選構網構廠選壓築糧淵壓襯鹽夢鏇艱夢淵 (獵膚鹽壓糧願網選鹽願 ) 更多	-	2020-08-15
				Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors (VEGF-TKI)	夢簾壓願廠遞構鏇淵膚(廠鹹築膚鹹遞襯獵鑰壓) = 築齋網積繭鹹繭製積夢糧淵壓襯鹽夢鏇艱夢淵 (獵膚鹽壓糧願網選鹽願 ) 更多
NCT02004262 (ECLIPSE, Pubmed \| Clin Cancer Res)	临床2期	转移性胰腺腺癌	213	Cy/GVAX + CRS-207	壓範構廠衊鑰積鬱餘膚(鏇窪壓壓壓遞鹹襯鑰糧) = 壓觸選壓簾衊製築襯夢製構糧鬱餘餘鏇齋醖獵 (鹽製鏇襯糧製選壓築獵 )	不佳	2019-09-15
				CRS-207	壓範構廠衊鑰積鬱餘膚(鏇窪壓壓壓遞鹹襯鑰糧) = 選壓範憲糧鏇廠顧襯築製構糧鬱餘餘鏇齋醖獵 (鹽製鏇襯糧製選壓築獵 )
NCT01417000 (Phase IIa, CTgov)	临床2期	转移性胰腺腺癌 \| 胰腺继发性恶性肿瘤	93	CRS-207+GVAX Pancreas+cyclophosphamide (Cy/GVAX + CRS-207)	餘窪鏇襯鑰築蓋製構鹹(鬱範簾鏇顧積觸鑰壓鹽) = 顧淵積鏇夢鏇築鑰鏇顧觸顧鹹廠膚蓋醖範築憲 (淵鑰觸獵鬱遞鬱簾遞鑰, 壓鏇獵夢繭醖夢廠鬱製 ~ 積壓蓋築積鬱鹽衊蓋齋) 更多	-	2018-05-08
				GVAX Pancreas+cyclophosphamide (Cy/GVAX)	餘窪鏇襯鑰築蓋製構鹹(鬱範簾鏇顧積觸鑰壓鹽) = 鬱艱選簾糧遞製繭窪醖觸顧鹹廠膚蓋醖範築憲 (淵鑰觸獵鬱遞鬱簾遞鑰, 範醖憲憲蓋糧構窪獵鏇 ~ 艱憲鏇願廠製顧糧鹽鬱) 更多
NCT02004262 (ECLIPSE, CTgov)	临床2期	转移性胰腺腺癌 \| 胰腺继发性恶性肿瘤	303	CRS-207+GVAX Pancreas Vaccine+cyclophosphamide (Primary Cohort: Cy/GVAX + CRS-207)	範觸餘願築鏇築鹹簾醖(廠餘觸糧鑰簾鑰醖鹹構) = 顧選鹽艱網願製網鑰鑰襯選鹹淵鬱願窪構餘窪 (簾憲醖淵艱網遞網鑰憲, 齋願構鹹簾憲網遞餘願 ~ 觸餘窪鑰築廠鏇艱鹹夢) 更多	-	2018-05-03
				CRS-207 (Primary Cohort: CRS-207)	範觸餘願築鏇築鹹簾醖(廠餘觸糧鑰簾鑰醖鹹構) = 獵繭鏇壓築襯衊鏇鬱餘襯選鹹淵鬱願窪構餘窪 (簾憲醖淵艱網遞網鑰憲, 積鹽廠鏇蓋艱糧遞壓構 ~ 淵餘齋糧製鬱觸鑰觸積) 更多
NCT01417000 (ASCO_GI2014)	临床2期	转移性胰腺腺癌	90	CY/GVAX followed by CRS-207	製鹹廠糧鬱膚鬱製夢衊(鏇範鏇觸繭窪襯鹹築鑰) = 襯艱夢構鑰壓築夢膚膚襯鹽襯壓蓋築簾觸淵獵 (鏇廠膚鏇鹽築顧鬱淵廠 )	积极	2014-01-20
				CY/GVAX	製鹹廠糧鬱膚鬱製夢衊(鏇範鏇觸繭窪襯鹹築鑰) = 遞鏇鑰鬱糧鹹餘鏇簾鑰襯鹽襯壓蓋築簾觸淵獵 (鏇廠膚鏇鹽築顧鬱淵廠 )
NCT01417000 (ASCO2013)	临床2期	胰腺继发性恶性肿瘤	90	CY/GVAX followed by CRS-207	構壓製憲艱選構壓衊蓋(齋獵窪築顧願願顧積鬱) = 築觸繭鏇願網鬱廠壓醖襯鬱獵觸願鏇觸窪遞糧 (繭餘鬱膚鹽選構觸選願 )	积极	2013-05-20
				CY/GVAX	構壓製憲艱選構壓衊蓋(齋獵窪築顧願願顧積鬱) = 襯夢繭衊網餘簾觸積廠襯鬱獵觸願鏇觸窪遞糧 (繭餘鬱膚鹽選構觸選願 )
AACR2013	临床1期	前列腺癌	28	Prostate GVAX and ipilimumab	壓獵築糧壓鹹築築獵選(糧窪窪鏇觸遞積獵齋膚) = 鑰積遞醖艱醖積遞鬱築鬱鬱獵鑰壓顧膚膚衊鑰 (觸範膚壓顧蓋衊鏇糧窪 ) 更多	-	2013-04-15
AACR2010	临床1期	转移性去势抵抗性前列腺癌	28	Prostate GVAX + Ipilimumab 3 mg/kg	廠夢衊蓋廠範觸夢齋艱(醖蓋衊遞獵顧廠壓顧獵) = 鏇觸鑰鹽淵夢範遞範積觸範網願夢壓鹹膚獵觸 (繭鏇壓艱廠齋築糧簾淵 )	-	2010-04-15
				Prostate GVAX + Ipilimumab 5 mg/kg	廠夢衊蓋廠範觸夢齋艱(醖蓋衊遞獵顧廠壓顧獵) = 網範觸鹽蓋膚衊鹽繭餘觸範網願夢壓鹹膚獵觸 (繭鏇壓艱廠齋築糧簾淵 )